Q&A with Adam Freund of Arda Therapeutics
Founder & CEO
Luminary/Mercury Series Series:
Arda is pioneering cell depletion for inflammation, immunology, and related indications. We leverage our proprietary, single-cell-based discovery engine to nominate target biology that can tag very specific pathogenic sub-populations of cells, then eliminate those cells via targeted biologics (ADCs, TCEs, etc).
Lead assets against novel targets deplete pathogenic fibroblasts in pulmonary fibrosis and have demonstrated substantial preclinical efficacy. Now in lead optimization with proprietary, state-of-the-art chemistry and a straightforward path to development candidate selection by Q1 2025.
In vivo efficacy demonstrated for multiple additional targets, tissues, cell types, and indications. Pipeline is focused on large market opportunities with well-established regulatory paths within fibrotic and inflammatory disease space.
An experienced team with decades of drug discovery and development experience, single-cell computational biology know-how, and pathogenic cell depletion expertise.
Strong founding seed syndicate with a16z, GV, Village Global, Longevity Fund, and others in early 2022.
Raising to reach DC for 1-2 programs and drive a Series A in 18 months, which will fund through clinical proof of concept.
Join us for a private Family Office Insights Mercury Series Webinar featuring Adam Freund of Arda Therapeutics.
Traditional pharmaceuticals modulate individual proteins and signaling pathways, aiming to restore tissue and organ function. However, declining drug approval rates and incremental therapeutic improvements demonstrate that this approach is reaching its limits; the low-hanging fruit has been picked. Arda Therapeutics offers a groundbreaking alternative: target cells, not pathways.
Arda’s unique strategy focuses on removing the pathogenic cells responsible for chronic diseases such as fibrosis and inflammation. By employing a sophisticated single-cell-based discovery engine, Arda identifies these cells and their surface markers with unprecedented precision. Their targeted biologics eliminate only the harmful cells, preserving healthy tissue and offering substantially greater efficacy than modulating individual protein targets.
The Arda team harnesses advanced computational biology and extensive drug development expertise, combined with deep know-how in non-oncology cell depletion. With multiple therapeutic programs in development and plans for further expansion, Arda is not just developing treatments; they are transforming the future of medicine.
June 10, 2024 at 2:15pm-3:15pm EST
RSVP & Confirmation Required
Investors Only Pleas
Family Office Insights is a voluntary, “opt-in” collaborative peer-to-peer community of single family offices, qualified investors and institutional investors. Join the community here www.familyofficeinsights.com
Adam Freund of Arda Therapeutics
* 19 years in life science R&D
* >20 publications and patents, >9,000 citations.
* PhD at Berkeley, postdoc at Stanford, PI and team lead at Calico Life Sciences.
* Initiated multiple therapeutic programs now in the clinic.
* Has grown a company from ~15 to 200+ employees.
* Experienced leader and team builder with extensive collaborative network.
Contact Adam: adam@ardatx.com